AbbVie Share Holder Equity 2010-2024 | ABBV

AbbVie share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • AbbVie share holder equity for the quarter ending March 31, 2024 was $8.047B, a 39.51% decline year-over-year.
  • AbbVie share holder equity for 2023 was $10.397B, a 39.86% decline from 2022.
  • AbbVie share holder equity for 2022 was $17.287B, a 11.99% increase from 2021.
  • AbbVie share holder equity for 2021 was $15.436B, a 17.86% increase from 2020.
AbbVie Annual Share Holder Equity
(Millions of US $)
2023 $10,397
2022 $17,287
2021 $15,436
2020 $13,097
2019 $-8,172
2018 $-8,446
2017 $5,097
2016 $4,636
2015 $3,945
2014 $1,742
2013 $4,492
2012 $3,363
2011 $11,932
2010 $15,703
2009 $0
AbbVie Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $8,047
2023-12-31 $10,397
2023-09-30 $12,129
2023-06-30 $12,898
2023-03-31 $13,303
2022-12-31 $17,287
2022-09-30 $16,027
2022-06-30 $14,688
2022-03-31 $16,314
2021-12-31 $15,436
2021-09-30 $13,577
2021-06-30 $12,594
2021-03-31 $13,733
2020-12-31 $13,097
2020-09-30 $15,289
2020-06-30 $14,732
2020-03-31 $-7,415
2019-12-31 $-8,172
2019-09-30 $-8,226
2019-06-30 $-8,566
2019-03-31 $-7,826
2018-12-31 $-8,446
2018-09-30 $-2,921
2018-06-30 $-3,375
2018-03-31 $3,553
2017-12-31 $5,097
2017-09-30 $6,687
2017-06-30 $6,009
2017-03-31 $4,998
2016-12-31 $4,636
2016-09-30 $6,469
2016-06-30 $5,640
2016-03-31 $4,643
2015-12-31 $3,945
2015-09-30 $4,863
2015-06-30 $5,504
2015-03-31 $1,377
2014-12-31 $1,742
2014-09-30 $4,645
2014-06-30 $5,218
2014-03-31 $4,697
2013-12-31 $4,492
2013-09-30 $3,577
2013-06-30 $3,558
2013-03-31 $2,957
2012-12-31 $3,363
2012-09-30 $15,669
2012-06-30 $11,505
2012-03-31 $12,051
2011-12-31 $11,932
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $15,703
2009-12-31 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $305.760B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.732B 120.64
Novo Nordisk (NVO) Denmark $598.098B 45.96
Johnson & Johnson (JNJ) United States $366.658B 14.54
Merck (MRK) United States $315.030B 57.32
AstraZeneca (AZN) United Kingdom $245.469B 21.34
Novartis AG (NVS) Switzerland $220.139B 15.30
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $127.725B 12.04
Innoviva (INVA) United States $1.113B 7.82